Short-term efficacy of thyroid hormone supplementation for patients with Down syndrome and low-borderline thyroid function.

Abstract

The thyroid function of 44 subjects with Down syndrome who were between 2 and 51 years of age was assessed. Three patients (7%) had hypothyroidism, and in 2 of them high titers of antimicrosomal antibody were detected. Seven additional subjects (16%) had low-borderline thyroid function, 6 with elevated thyroid stimulating hormone. These 7 subjects constituted the cohort for an evaluation of the short-term benefits of thyroid hormone supplementation in the low-borderline thyroid functional state. A double-blind crossover drug placebo trial failed to document any cognitive, social, response time, or physical changes attributable to the 8- to 14-week drug treatment period compared to an untreated matched control group. Results provided no evidence for the efficacy of short-term thyroid hormone therapy for this population.

• Authors: E Tirosh, Y Taub, A Scher, M Jaffe, Z Hochberg
• Journal: American journal of mental retardation : AJMR (Am J Ment Retard) Vol. 93 Issue 6 Pg. 652-6 (May 1989) ISSN: 0895-8017 [Print] United States
• PMID: 2524203 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Thyroxine

Topics

• Adolescent
• Adult
• Behavior (drug effects)
• Child
• Child, Preschool
• Down Syndrome (complications)
• Female
• Humans
• Hypothyroidism (complications, drug therapy)
• Male
• Middle Aged
• Thyroxine (pharmacology)